Purpose To report on a case of osteonecrosis of the jaw (ONJ) in a patient treated with clodronate, an alkylbiphosphonate, and to draw attention to the risk of ONJ following treatment with all biphosphonates, whether they are alkyl-or amino-biphosphonates. Case report Beginning at age 58 years, a female patient took clodronate for almost 13 years for a metastatic bone cancer. She also underwent chemotherapy and radiotherapy. Three months after the end of biphosphonate therapy, she suffered from toothache, and tooth 27 (left maxillary second molar) was extracted. A maxillary focus of osteitis with an oral sinus communication was discovered, and a maxillofacial denture prosthesis was grafted in September 2006. Some days later, the patient consulted her dentist for an ulceration of the oral cavity floor in front of tooth 33 (left mandibular canine) extending to the left inferior side of the lip. In October 2006, teeth 33 and 34 (left mandibular first premolar) were extracted. No secondary infection occurred. A complete healing was only observed 3 months after the last extraction. ONJ due to alkylbiphosphonate treatment was diagnosed as bone reconstruction and mucous cicatrisation were delayed. Methods A systematic review was carried out to identify all cases of alkylbiphosphonate-induced ONJ by searching the Medline and Cochrane databases using 'osteonecrosis of the jaw', 'jaw diseases', 'osteonecrosis', 'diphosphonate', 'biphosphonate' (amino-, alkyl-or the international nonproprietary name) as the main search items. The search was limited to English-and French-language articles published between 1966 and February 2010. Results Our search identified 27 cases of alkylbiphosphonateinduced ONJ in the literature. Among these cases, only ten patients were on alkylbiphosphonate monotherapy; in the other cases, aminobiphosphonates had also been used. The clinical presentation of the alkylbiphosphonate-induced ONJ was similar to that most often encountered with aminobiphosphonate treatment. The duration of exposure before onset was higher with alkylbiphosphonates than with aminobiphosphonates, and dental procedures before ONJ were frequent. Conclusion Osteonecrosis of the jaw has been widely reported with various aminobiphosphonates, but data on the role of alkylbiphosphonates are scarce. As these latter drugs are less potent, a high cumulative dose through long-term exposure would appear to be necessary and would favour ONJ. Although the degree of risk for ONJ occurrence in patients on alkylbiphosphonates remains uncertain, it would be wise to reconsider carefully the indications for using these agents and to apply preventive measures as is currently done for aminobiphosphonates.
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Introduction
Biphosphonates are synthetic analogues of pyrophosphate, an endogenous regulator of bone mineralization. In this heterogeneous family, two types of biphosphonates share a common phosphorus-carbon-phosphorus backbone: (1) alkylbiphosphonates, also called first-generation biphosphonates (clodronate, etidronate and tiludronate), which are devoid of amine function on the lateral chain; (2) aminobiphosphonates, which are considered to be second-(alendronate, pamidronate) or third-generation biphosphonates (zoledronate, risedronate, ibandronate) ( Table 1 ). The amine function is responsible for the increased potency of the biphosphonates: the inhibition of bone resorption is greater with aminobiphosphonate than with alkylbiphosphonates [1, 2] . Biphosphonates are used to treat numerous disorders that affect bone, such as osteoporosis, bone metastases, hypercalcemia of malignancy and multiple myeloma (Table 1) . Since aminobiphosphonates have much stronger activities than alkylbiphosphonates, the former are more widely used.
Unfortunately, biphosphonates induce a serious adverse effect-osteonecrosis of the jaw (ONJ). Osteonecrosis is a necrotic lesion of bone tissue characterized by a slow progression and by failure to heal spontaneously. It manifests itself by pain, soft-tissue swelling, gingival bleeding, exposed bone and non-healing extraction socket, and it induces serious sequelae. These lesions can develop into an osteomyelitis with purulent material often containing Actinomyces. Radiographs may show regions of mottled bone [3, 4] . A differential diagnosis of biphosphonate related-ONJ can be considered if all of the following three characteristics are present: (1) patient is currently undergoing or has previously received treatment with a biphosphonate; (2) patient has an exposed bone in the maxillofacial region that has persisted for >8 weeks; (3) patient has no history of radiotherapy to the jaw [5] .
The first ONJ cases due to aminobiphosphonate treatment were reported in 2003-2004 by Marx et al. [6] and Ruggiero et al. [7] . Since then, more than 3,000 cases have been published [8] , almost all of which have been linked to aminobiphosphonate treatments. Risk factors such as administration route, indication, duration of treatment and administrated cumulative dose of biphosphonates have already been described. Several other factors also seem to favour ONJ occurrence, including dental risk factors (tooth extraction, periodontal disease, other surgical or invasive dental procedure), which were present in nearly 70% of reported cases, cancer and anti-cancer therapy (local radiotherapy, chemotherapy etc), corticosteroids and various comorbidities (diabetes, anaemia, among others) [9] [10] [11] [12] . Only a few cases have been reported with alkylbiphosphonates.
We report here on a case of ONJ in a patient who received an alkylbiphosphonate, clodronate, for treatment of bone metastasis from breast cancer. After a systematic review to identify all published cases of alkylbiphosphonate-induced ONJ, we discuss the risk factors of biphosphonate-induced ONJ.
Case report
In March 1987, the patient, then a 58-year-old woman, was operated on for cancer of the right breast and subsequently underwent locoregional irradiation. Six years later, she had bone metastasis (sternum and L4) and was treated with chemotherapy (5-fluorouracile, carboplatin, vinorelbine, mitoxantrone), hormone therapy (aminogluthetimide, leu- In May 2006, the patient consulted a dentist for the occurrence of pain near tooth 27 (left maxillary second molar). One month later, this infected tooth was extracted, and a maxillary focus of osteitis with an oral sinus communication was discovered. A maxillofacial denture prosthesis was grafted in September 2006. Some days later, the patient again consulted her dentist, this time for an ulceration of the oral cavity floor in front of tooth 33 (left mandibular canine) extending to the left inferior side of the lip. In October 2006, teeth 33 and 34 (left mandibular first premolar) were extracted. No secondary infection occurred. A complete healing was only observed 3 months after the last extraction. Based on the delayed bone reconstruction and mucous cicatrisation, we diagnosed ONJ.
Analysis using the Naranjo probability scale revealed that an association between clodronate and ONJ was probable [13] .
Case reports of alkylbiphosphonate-induced ONJ
A systematic review of the literature was performed by searching the Medline and Cochrane databases using Mesh and non-Mesh terms. The main search terms were 'osteonecrosis of the jaw', 'jaw diseases', 'osteonecrosis', 'diphosphonate' and 'biphosphonate' (amino-, alkyl-or international nonproprietary name). The search was limited to English-and French-language articles published between 1966 and February 2010. Titles and available abstracts were scanned for relevance in order to identify paper requiring further consideration. The literature review was completed by a search done by hand accessing the references cited in all relevant publications. Among the 1,211 references identified, nine articles were selected in which cases of ONJ were identified as being induced by alkylbiphosphonate treatment.
The results of the search are shown in Table 2 . Twentyseven cases were identified: 25 with clodronate and two with etidronate [10, [14] [15] [16] [17] [18] [19] [20] [21] . Among these 27 cases, clodronate was used alone in eight cases and etidronate alone in two cases. Indications of biphosphonates were varied: six patients had multiple myeloma, 12 had solid cancers, five had osteoporosis, one had solid cancer associated with osteoporosis and two patients required orthopedic surgery (one indication was unknown). Eighteen (67%) of the patients had required dental procedures. The mean duration of exposure before onset of ONJ was 35 months when clodronate or etidronate was used alone.
Discussion
Reported cases of ONJ have been less frequently associated with alkylbiphosphonate treatments (27 cases to date plus the one discussed here) than with aminobiphosphonate treatments (>3,000). Our patient showed characteristics similar to those reported in earlier cases of alkylbiphosphonate-induced ONJ, namely, an indication of malignant disease and long period of alkylbiphosphonate treatment [in our case, almost 13 years (151 months) with a cumulative amount of close to 7 kg]. Other risk factors of ONJ are chemotherapy and dental procedure.
The main risk factors for developing ONJ linked to biphosphonate use are administration route, indication and duration of exposure.
Biphosphonates given intravenously are usually considered to be more potent than those administered by the oral route and, therefore, more of a risk factor for inducing ONJ, as evidenced by the higher estimated incidence of ONJ (0-10%) in patients receiving intravenous biphosphonates than in patients on oral therapy (<1%) [22] . The risk depends on the specific biphosphonate given, the dose, the duration of treatment and the dental history of the patient. However, the incidence rate also depends on the reporting source. Manufacturer-sponsored epidemiological studies have reported incidence estimates of ONJ of 0.1-1.8% [23, 24] , while independent epidemiological studies from clinicians and the International Myeloma Foundation report somewhat higher incidence estimates of between 5 and 10%. The fairly low incidence of ONJ with oral biphosphonates could also be related to a poor bioavailability and to poor treatment compliance. As ONJ is now a well-known adverse effect of intravenous biphosphonates, one can be falsely reassuring about the safety of oral biphosphonates. According to Yarom et al., of all the ONJ patients in case series reported in the literature, the relative proportion of orally administrated biphosphonate-induced ONJ ranges from 2.5 to 27.3% [25] . In most cases, alendronate, an aminobiphosphonate, was the oral biphosphonate mentioned because it is the most widely used oral biphosphonate. These authors reported on a personal series of 11 female patients (8.9% of their ONJ patients on biphosphonates) who developed ONJ after monotherapy with oral biphosphonate. The extent of the relative risk with oral biphosphonate treatment is still being debated. In a casecontrol study nested within a cardiovascular cohort, Etminan et or other metabolic diseases was not causally linked to the development of ONJ [28] The administration route seen previously as a risk is in fact linked to the indication. ONJ is more often reported in patients with cancer, with the most frequently reported cancers being multiple myeloma, breast, prostate and lung cancers and all cases with bone metastasis. However, the type of malignant disease does not seem to be associated with an increased ONJ incidence [11, [29] [30] [31] . In a recent meta-analysis performed on biphosphonates used in breast cancer treatment, ONJ occurred in 13 of the 5,312 patients receiving biphosphonates (0.24%) versus one of the 5,382 patients (0.018%) who were on placebo. In all cases, zoledronate, an aminobiphosphonate, was used. Treatment with zoledronate was significantly associated to the occurrence of ONJ [odds ratio (OR) 3.23, 95% CI 1.7-8] compared with no use [32] . ONJ has also been reported in patients with non-malignant conditions, such as osteoporosis [20, 33] . In a retrospective survey, the frequency of ONJ in osteoporotic patients was 0.01-0.04% (mainly on weekly oral alendronate), and if a tooth extraction was carried out, the frequency increased up to 0.09-0.34% [12] . In a review on ONJ in patients with osteoporosis treated with biphosphonates, the authors identified 26 cases in 11 publications. The biphosphonates prescribed were alendronate (23 patients), risedronate, pamidronate and alendronate and zoledronate (1 patient each); all of these are aminobiphosphonates [34] . The most recent case series reported on 24 non-oncologic patients with ONJ who were treated with biphosphonates: 15 patients with alendronate, two with risedronate, two with ibandronate, three with clodronate, one with clodronate+alendronate and one with clodronate+risedronate. Five of these cases involved the use of alkylbiphosphonates. The indication was osteoporosis in 20 of the 24 patients [20] .
Drug exposure is also an important risk factor. In one study, the median duration of exposure to bisphosphonates was 39.3 months for patients with ONJ compared with 19 months for patients with no ONJ (p=0.001) [30] . When biphosphonates are administered by the intravenous route to treat skeletal complications of malignancy, the annual doses of pamidronate or zoledronate (two aminobiphosphonates), are four-to tenfold higher than those used to treat osteoporosis [35] . The mean time from first drug exposure to occurrence of ONJ is variable according to the drug used: 9.4-18 months for zoledronate, 14.3-24 months for pamidronate and 12.1 months for pamidronate+zoledronate [6, 7, 12, 36, 37] . The estimated cumulative hazard rate of developing ONJ has been reported to be 1% at 1 year and 21% at 3 years or 15% at 4 years [30, 38] with zoledronate and 7% at 3 years with pamidronate [30] . In cases of oral use, patients in some studies received biphosphonate for a mean duration of 24-40 months before the occurrence of ONJ [12, Etidronate (1 [10, [14] [15] [16] [17] [18] [19] [20] [21] ; no case has been found with tiludronate. The clinical presentation of alkylbiphosphonate-induced ONJ is very similar to that of aminobiphosphonate-induced ONJ. In the reported cases, the patients underwent dental procedures at the same frequency as those receiving aminobiphosphonates (67 vs. 70%) [11, 12] . The duration of exposure before the onset of ONJ seemed to be longer with alkylbiphosphonates than with aminobiphosphonates: 35 months when clodronate or etidronate were used alone versus 9-18 months for zoledronate and 14-24 months for pamidronate, both used alone [6, 7, 12, 15, [18] [19] [20] [21] 36] .
Of the biphosphonates, the ones most likely to induce ONJ are aminobiphosphonates [33, 40, 41] , possibly because they are more potent than alkylbiphosphonates. Indeed, pamidronate, alendronate and zoledronate are respectively 10-, 100-and 1,000-fold more potent than clodronate. The exact mechanism involved in the occurrence of ONJ with biphosphonate is unknown. Different pharmacological mechanisms of biphosphonate activity have been reported, and mechanisms also seem to differ according to the biphosphonate generation. Osteoclasts metabolize alkylbiphosphonates into cytotoxic adenosine triphosphate analogues that accumulate in osteoclasts and induce apoptosis. Aminobiphosphonates inhibit the mevalonate pathway implicated in cytoskeleton organization [40] . The cortical bone of the mandibule has a much higher turnover than appendicular sites. Therefore, biphosphonates will be selectively concentrated into the jaw, thereby changing the balance of bone resorption and bone formation and resulting in reduced bone turnover. The biphosphonate concentration in the bone of the jaw may be sufficient to be directly toxic to the oral epithelium [42] . Biphosphonates inhibit proliferation, differentiation and migration of osteoclast precursors. Aminobiphosphonates also inhibit various proteins involved in cancer growth and metastasis and have an antiangiogenic effect [43] .
Bone necrosis is considered to be time and dose dependant because of the long half-life of biphosphonates in bones [33] , which can amount to 10 years. Although the activity of clodronate is weaker than that of aminobiphosphonates, the osteoclast-inhibiting action of such a huge cumulated dose (7 kg in our case) was probably marked and protracted. We there conclude that it is essential to obtain a complete history for every patient treated with biphosphonates in whom ONJ is suspected.
Finally, it should be noted that as the action mechanisms of alkylbiphosphonates and aminobiphosphonates are slightly different and as aminobiphosphonates are more potent, these latter drugs tend to be prescribed more often.
Conclusion
The occurrence of ONJ is now a well-known adverse event associated with relatively long biphosphonate treatment. The intravenous route, duration of exposure, cumulative dose and aminobiphosphonates are recognized risk factors. Biphosphonates-seldom alkylbiphosphonates-are more likely to be involved in ONJ. The risk profile of patients treated with alkylbiphosphonates was similar to that of patients receiving aminobiphosphonate treatments (patients with malignant disease and history of recent dental procedures). As alkylbiphosphonates are less potent, longterm exposure seems to be necessary for a high cumulative dose and the development of ONJ. Two hypotheses could be advanced to explain the small numbers of case-reports with alkylbiphosphonates:
-alkylbiphosphonates are prescribed less often than aminobiphosphonates; -as the duration of treatment before ONJ occurrence is longer with alkylbiphosphonates, the relationship between ONJ and alkylbiphosphonate intake is more difficult to assess; however, in most of the cases reported with alkylbiphosphonates, aminobiphosphonates were also used.
Finally, there is probably a trend towards a moderate over-risk with alkylbiphosphonates, but data are still insufficient to quantitate this relationship with ONJ as we found only 28 cases of alkylbiphosphonate-induced ONJ (27 in the literature plus our case). Among these cases, only 40% of the patients were administered alkylbiphosphonates alone.
A Mayo Clinic consensus-statement for the use of bisphosphonates in multiple myeloma has recently been published. The statement recommends that the duration of biphosphonate therapy should no longer be indefinite and that pamidronate is the biphosphonate of choice [44] among the aminobiphosphonates. The International Myeloma Working Group recommends clodronate [45] .
Physicians should be alerted to the risk of ONJ occurrence in patients on alkylbiphosphonates (clodronate, etidronate, tiludronate). As there is no effective therapy for biphosphonate-associated ONJ, specific measures should to be taken, such as dental care before the initiation of therapy, communication between professionals prescribing biphosphonates and dental professionals and careful choice of the indications for use.
